2
UNITEK HAYWARD Pharmacology Chapters 1, 2, 3 Exam || || || || || || || ||
with verified detailed answers || || ||
Which description best defines a medication?
|| || || || ||
A) Chemical substance that requires a prescription by a health professional
|| || || || || || || || || ||
B) Drug used for a therapeutic effect to treat or prevent an illness
|| || || || || || || || || || || ||
C) Pharmacologic preparation used to reverse disease
|| || || || || ||
D) Plant, animal, or mineral substance that prevents disease - ✔✔B) Drug used for a
|| || || || || || || || || || || || || || ||
therapeutic effect to treat or prevent an illness || || || || || || ||
Medications are drugs used for their therapeutic effects. A therapeutic effect can be the || || || || || || || || || || || || || ||
prevention or treatment of disease. All medications do not require a prescription. Specifying
|| || || || || || || || || || || ||
a certain action is not the best definition of a medication because it is incomplete.
|| || || || || || || || || || || || || || ||
What is the trade name of a drug?
|| || || || || || ||
A) The proprietary name of the drug given by a manufacturer.
|| || || || || || || || || ||
B) The chemical name of the drug given by its developer.
|| || || || || || || || || ||
C) The name given to the drug by the U.S. Food and Drug Administration (FDA).
|| || || || || || || || || || || || || ||
D) The name under which the drug is listed in the U.S. Pharmacopeia. - ✔✔A) The
|| || || || || || || || || || || || || || || ||
proprietary name of the drug given by a manufacturer. || || || || || || || ||
The trade or brand name is the proprietary name given to the drug by its manufacturer. The
|| || || || || || || || || || || || || || || || ||
same drug produced by different companies has one generic name but may have many
|| || || || || || || || || || || || || ||
trade names. The trade name is trademark protected and can be used only by its
|| || || || || || || || || || || || || || ||
manufacturer. The drug may be listed under more than one name in the Pharmacopeia. The || || || || || || || || || || || || || ||
book is used to provide standards for identity, quality, strength, and purity of substances
|| || || || || || || || || || || || || || ||
used in healthcare practice. The trade name is not given to a drug by the FDA. The
|| || || || || || || || || || || || || || || || ||
chemical name is the exact chemical constitution of the drug and the exact placing of its
|| || || || || || || || || || || || || || || ||
atoms or molecular groupings. || || ||
What is the MedWatch form used for?
|| || || || || ||
,2
A) Tracking numbers of prescriptions written for a specific drug
|| || || || || || || || ||
B) Assessing the acceptability of the drug to individual patients
|| || || || || || || || ||
C) Determining the therapeutic effectiveness of the drug
|| || || || || || ||
D) Identifying adverse effects of a drug in the general population - ✔✔D) Identifying
|| || || || || || || || || || || || || ||
adverse effects of a drug in the general population
|| || || || || || || ||
Healthcare practitioners make a significant contribution to the knowledge of drug safety by
|| || || || || || || || || || || || ||
reporting adverse effects to the FDA using the MedWatch program for the voluntary
|| || || || || || || || || || || || ||
reporting of adverse events and product problems. This method of identifying adverse
|| || || || || || || || || || || ||
effects of a drug in the general population is part of the postmarketing surveillance phase of
|| || || || || || || || || || || || || || || ||
drug development. More than 200,000 MedWatch forms are filed with the FDA annually.
|| || || || || || || || || || || || ||
MedWatch is not designed to track the numbers of prescriptions written for a specific drug;
|| || || || || || || || || || || || || || ||
is not a program involved in determining the therapeutic effectiveness of a drug; and is not
|| || || || || || || || || || || || || || || ||
involved in assessing the acceptability of a drug to individual patients.
|| || || || || || || || || ||
Which statement about drug names is correct?
|| || || || || ||
A) Drugs are listed by their chemical names in the U.S. Pharmacopeia.
|| || || || || || || || || || ||
B) A drug may have multiple proprietary names.
|| || || || || || ||
C) The generic name is a trademarked name.
|| || || || || || ||
D) The official name must be used on all prescriptions. - ✔✔B) A drug may have multiple
|| || || || || || || || || || || || || || || || ||
proprietary names. ||
The proprietary name of a drug is a trade or brand name and is followed by the symbol ®.
|| || || || || || || || || || || || || || || || || || ||
Each manufacturer of a drug can register a proprietary name that can be used only by that
|| || || || || || || || || || || || || || || || ||
company. Thus a drug produced by more than one manufacturer can have multiple
|| || || || || || || || || || || || ||
proprietary names but only one generic name. Drugs are listed by their official names in the
|| || || || || || || || || || || || || || ||
U.S. Pharmacopeia. Generic names are not trademarked. Prescriptions can be written using
|| || || || || || || || || || || || ||
generic or trade names. || || ||
How do Schedule II drugs differ from Schedule V drugs?
|| || || || || || || || ||
A) Schedule V drugs have greater risk for toxicity.
|| || || || || || || ||
B) Schedule II drugs have less potential for abuse.
|| || || || || || || ||
, 2
C) Schedule V drugs lack accepted safety measures for use.
|| || || || || || || || ||
D) Schedule II drugs are more likely to cause dependence. - ✔✔D) Schedule II drugs are
|| || || || || || || || || || || || || || || ||
more likely to cause dependence.
|| || || ||
Schedule II drugs have a high potential for abuse that may lead to severe psychological or
|| || || || || || || || || || || || || || || ||
physical dependence. Schedule II drugs have more, not less, potential for abuse than
|| || || || || || || || || || || || ||
Schedule V drugs. Schedule II and Schedule V drugs have accepted guidelines for safe use.
|| || || || || || || || || || || || || || ||
Drugs in both schedules are not differentiated based on toxicity. There may be drugs in each
|| || || || || || || || || || || || || || ||
schedule that have high or low toxicity.
|| || || || || || ||
Which legislation was written to require companies to determine the safety of medications
|| || || || || || || || || || || || ||
before marketing? ||
A) The Federal Food, Drug, and Cosmetic Act of 1938
|| || || || || || || || ||
B) Durham Humphrey Amendment of 1952
|| || || || ||
C) The Kefauver Harris Drug Amendment of 1962
|| || || || || || ||
D) Controlled Substance Act of 1970 - ✔✔A) The Federal Food, Drug, and Cosmetic Act of
|| || || || || || || || || || || || || || || ||
1938
The Federal Food, Drug, and Cosmetic Act of 1938 (passed on June 25, 1938, and amended
|| || || || || || || || || || || || || || || ||
in 1952 and 1962) requires the FDA to determine the safety of drugs before marketing and
|| || || || || || || || || || || || || || || ||
to ensure that certain labeling specifications and standards in advertising are met in the
|| || || || || || || || || || || || || ||
marketing of products. Manufacturers are required to submit new drug applications to the
|| || || || || || || || || || || || ||
FDA for review of safety studies before products can be released. The Durham Humphrey
|| || || || || || || || || || || || || ||
Amendment of 1952 was passed to tighten control over prescription drugs by restricting the|| || || || || || || || || || || || || ||
refilling of prescriptions. The Kefauver Harris Drug Amendment of 1962 was brought about
|| || || || || || || || || || || || ||
by the thalidomide tragedy. The amendment provides greater control and surveillance of the
|| || || || || || || || || || || ||
distribution and clinical testing of investigational drugs, and requires that a product be
|| || || || || || || || || || || || || ||
proven safe and effective before release for sale. The Controlled Substance Act of 1970 was
|| || || || || || || || || || || || || || ||
passed by Congress to improve the administration and regulation of manufacturing,
|| || || || || || || || || || ||
distributing, and dispensing of drugs that have been found necessary to be controlled.
|| || || || || || || || || || || ||
Which legislation was enacted to stimulate development and availability of drugs to treat
|| || || || || || || || || || || || ||
rare diseases? ||
A) The Orphan Drug Act
|| || || ||
UNITEK HAYWARD Pharmacology Chapters 1, 2, 3 Exam || || || || || || || ||
with verified detailed answers || || ||
Which description best defines a medication?
|| || || || ||
A) Chemical substance that requires a prescription by a health professional
|| || || || || || || || || ||
B) Drug used for a therapeutic effect to treat or prevent an illness
|| || || || || || || || || || || ||
C) Pharmacologic preparation used to reverse disease
|| || || || || ||
D) Plant, animal, or mineral substance that prevents disease - ✔✔B) Drug used for a
|| || || || || || || || || || || || || || ||
therapeutic effect to treat or prevent an illness || || || || || || ||
Medications are drugs used for their therapeutic effects. A therapeutic effect can be the || || || || || || || || || || || || || ||
prevention or treatment of disease. All medications do not require a prescription. Specifying
|| || || || || || || || || || || ||
a certain action is not the best definition of a medication because it is incomplete.
|| || || || || || || || || || || || || || ||
What is the trade name of a drug?
|| || || || || || ||
A) The proprietary name of the drug given by a manufacturer.
|| || || || || || || || || ||
B) The chemical name of the drug given by its developer.
|| || || || || || || || || ||
C) The name given to the drug by the U.S. Food and Drug Administration (FDA).
|| || || || || || || || || || || || || ||
D) The name under which the drug is listed in the U.S. Pharmacopeia. - ✔✔A) The
|| || || || || || || || || || || || || || || ||
proprietary name of the drug given by a manufacturer. || || || || || || || ||
The trade or brand name is the proprietary name given to the drug by its manufacturer. The
|| || || || || || || || || || || || || || || || ||
same drug produced by different companies has one generic name but may have many
|| || || || || || || || || || || || || ||
trade names. The trade name is trademark protected and can be used only by its
|| || || || || || || || || || || || || || ||
manufacturer. The drug may be listed under more than one name in the Pharmacopeia. The || || || || || || || || || || || || || ||
book is used to provide standards for identity, quality, strength, and purity of substances
|| || || || || || || || || || || || || || ||
used in healthcare practice. The trade name is not given to a drug by the FDA. The
|| || || || || || || || || || || || || || || || ||
chemical name is the exact chemical constitution of the drug and the exact placing of its
|| || || || || || || || || || || || || || || ||
atoms or molecular groupings. || || ||
What is the MedWatch form used for?
|| || || || || ||
,2
A) Tracking numbers of prescriptions written for a specific drug
|| || || || || || || || ||
B) Assessing the acceptability of the drug to individual patients
|| || || || || || || || ||
C) Determining the therapeutic effectiveness of the drug
|| || || || || || ||
D) Identifying adverse effects of a drug in the general population - ✔✔D) Identifying
|| || || || || || || || || || || || || ||
adverse effects of a drug in the general population
|| || || || || || || ||
Healthcare practitioners make a significant contribution to the knowledge of drug safety by
|| || || || || || || || || || || || ||
reporting adverse effects to the FDA using the MedWatch program for the voluntary
|| || || || || || || || || || || || ||
reporting of adverse events and product problems. This method of identifying adverse
|| || || || || || || || || || || ||
effects of a drug in the general population is part of the postmarketing surveillance phase of
|| || || || || || || || || || || || || || || ||
drug development. More than 200,000 MedWatch forms are filed with the FDA annually.
|| || || || || || || || || || || || ||
MedWatch is not designed to track the numbers of prescriptions written for a specific drug;
|| || || || || || || || || || || || || || ||
is not a program involved in determining the therapeutic effectiveness of a drug; and is not
|| || || || || || || || || || || || || || || ||
involved in assessing the acceptability of a drug to individual patients.
|| || || || || || || || || ||
Which statement about drug names is correct?
|| || || || || ||
A) Drugs are listed by their chemical names in the U.S. Pharmacopeia.
|| || || || || || || || || || ||
B) A drug may have multiple proprietary names.
|| || || || || || ||
C) The generic name is a trademarked name.
|| || || || || || ||
D) The official name must be used on all prescriptions. - ✔✔B) A drug may have multiple
|| || || || || || || || || || || || || || || || ||
proprietary names. ||
The proprietary name of a drug is a trade or brand name and is followed by the symbol ®.
|| || || || || || || || || || || || || || || || || || ||
Each manufacturer of a drug can register a proprietary name that can be used only by that
|| || || || || || || || || || || || || || || || ||
company. Thus a drug produced by more than one manufacturer can have multiple
|| || || || || || || || || || || || ||
proprietary names but only one generic name. Drugs are listed by their official names in the
|| || || || || || || || || || || || || || ||
U.S. Pharmacopeia. Generic names are not trademarked. Prescriptions can be written using
|| || || || || || || || || || || || ||
generic or trade names. || || ||
How do Schedule II drugs differ from Schedule V drugs?
|| || || || || || || || ||
A) Schedule V drugs have greater risk for toxicity.
|| || || || || || || ||
B) Schedule II drugs have less potential for abuse.
|| || || || || || || ||
, 2
C) Schedule V drugs lack accepted safety measures for use.
|| || || || || || || || ||
D) Schedule II drugs are more likely to cause dependence. - ✔✔D) Schedule II drugs are
|| || || || || || || || || || || || || || || ||
more likely to cause dependence.
|| || || ||
Schedule II drugs have a high potential for abuse that may lead to severe psychological or
|| || || || || || || || || || || || || || || ||
physical dependence. Schedule II drugs have more, not less, potential for abuse than
|| || || || || || || || || || || || ||
Schedule V drugs. Schedule II and Schedule V drugs have accepted guidelines for safe use.
|| || || || || || || || || || || || || || ||
Drugs in both schedules are not differentiated based on toxicity. There may be drugs in each
|| || || || || || || || || || || || || || ||
schedule that have high or low toxicity.
|| || || || || || ||
Which legislation was written to require companies to determine the safety of medications
|| || || || || || || || || || || || ||
before marketing? ||
A) The Federal Food, Drug, and Cosmetic Act of 1938
|| || || || || || || || ||
B) Durham Humphrey Amendment of 1952
|| || || || ||
C) The Kefauver Harris Drug Amendment of 1962
|| || || || || || ||
D) Controlled Substance Act of 1970 - ✔✔A) The Federal Food, Drug, and Cosmetic Act of
|| || || || || || || || || || || || || || || ||
1938
The Federal Food, Drug, and Cosmetic Act of 1938 (passed on June 25, 1938, and amended
|| || || || || || || || || || || || || || || ||
in 1952 and 1962) requires the FDA to determine the safety of drugs before marketing and
|| || || || || || || || || || || || || || || ||
to ensure that certain labeling specifications and standards in advertising are met in the
|| || || || || || || || || || || || || ||
marketing of products. Manufacturers are required to submit new drug applications to the
|| || || || || || || || || || || || ||
FDA for review of safety studies before products can be released. The Durham Humphrey
|| || || || || || || || || || || || || ||
Amendment of 1952 was passed to tighten control over prescription drugs by restricting the|| || || || || || || || || || || || || ||
refilling of prescriptions. The Kefauver Harris Drug Amendment of 1962 was brought about
|| || || || || || || || || || || || ||
by the thalidomide tragedy. The amendment provides greater control and surveillance of the
|| || || || || || || || || || || ||
distribution and clinical testing of investigational drugs, and requires that a product be
|| || || || || || || || || || || || || ||
proven safe and effective before release for sale. The Controlled Substance Act of 1970 was
|| || || || || || || || || || || || || || ||
passed by Congress to improve the administration and regulation of manufacturing,
|| || || || || || || || || || ||
distributing, and dispensing of drugs that have been found necessary to be controlled.
|| || || || || || || || || || || ||
Which legislation was enacted to stimulate development and availability of drugs to treat
|| || || || || || || || || || || || ||
rare diseases? ||
A) The Orphan Drug Act
|| || || ||
